Diasome Pharmaceuticals is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company's pipeline includes novel, proprietary liver targeted insulins for both Type 1 and Type 2 diabetes patients that are currently being tested in multiple human clinical trials.
Market
Diabetes and Obesity
Location
Cleveland,
Ohio,
USA
Coinvestors
Black Beret Life Sciences, JDRF T1D Fund, McDonald Partners, Medicxi